{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022894","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.314308+00:00","generated_at":"2026-06-22T03:09:35.495594+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences Q3 revenue $7.4M, net loss $23.9M; discontinues PBCAR269A program","bullets":["Net loss of $23.9M ($0.22 loss per share) vs $11.3M loss ($0.19) in Q3 2021.","Revenue $7.4M, down 69% from $24M YoY; decrease primarily from absence of iECURE revenue.","Cash $212.1M; expects runway to fund operations through end of 2024.","Discontinued BCMA CAR T program PBCAR269A due to competitive landscape; no further clinical spending planned.","Planned clinical update for azer-cel (PBCAR0191) and PBCAR19B in late Q4 2022 or early Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022894","json":"https://secwatch.observer/filing/0000950170-22-022894.json","markdown":"https://secwatch.observer/filing/0000950170-22-022894.md","text":"https://secwatch.observer/filing/0000950170-22-022894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/0000950170-22-022894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/dtil-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:09:35.495594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9dbafa08aff7410f4fe21b9afeaf6c92eab084f","claim":"PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/0000950170-22-022894-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}